A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 6, 2007, Pages 768-778

  Schimmelmann, Benno Graf ^a   Mehler Wex, Claudia ^b   Lambert, Martin ^c   Schulze Zur Wiesch, Constanze ^c   Koch, Eginhard ^d   Flechtner, Hans Henning ^e   Gierow, Baerbel ^f   Maier, Joachim ^g   Meyer, Eberhard ^h   Schulte Markwort, Michael ^c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF ROSTOCK   (Germany)

^g GOETHE UNIVERSITY   (Germany)

^h Department of Child and Adolescent Neuropsychiatry ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROLACTIN; QUETIAPINE; THYROTROPIN; THYROXINE;

ABDOMINAL PAIN; ADOLESCENT; AKATHISIA; ANOVULATION; ARTICLE; ATTENTION; BODY MASS; CHILD PSYCHIATRY; CLINICAL TRIAL; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GERMANY; GYNECOMASTIA; HEADACHE; HUMAN; HYPOTHYROIDISM; INSOMNIA; LIBIDO; MAJOR CLINICAL STUDY; MALE; MENORRHAGIA; MULTICENTER STUDY; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RHINOPHARYNGITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN; WELLBEING; XEROSTOMIA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SLEEP STAGES; THYROXINE; TREATMENT FAILURE; WEIGHT GAIN;

EID: 38549107544     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2007.0048     Document Type: Article

References (40)

1. Agid O, Kapur S, Arenovich T, Zipursky RB: Delayed-onset hypothesis of antipsychotic action: A hypothesis tested and rejected. Arch Gen Psychiatry 60:1228-1235, 2003.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156:1686-1696, 1999.
3. American Psychiatric Association: Diagnostic Criteria from DSM-IV. Washington (DC), American Psychiatric Press, 1994.
4. American Academy of Child and Adolescent Psychiatry: Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 40(Suppl):4-23, 2001.
5. Arango C, Bernardo M: The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum Psychopharmacol 20:237-241, 2005.
6. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676, 1989.
7. Beer F, Heinrich H, Springer S, Ruth U, Freisleder FJ: Quetiapine in the treatment of psychotic adolescents: A case series of 23 patients with severe early onset psychosis. World J Biol Psychiatry 8:38-41, 2007.
8. Beratis S, Gabriel J, Hoidas S: Age at onset in subtypes of schizophrenic disorders. Schizophr Bull 20:287-296, 1994.
9. Castro-Fornieles J, Parellada M, Gonzalez-Pinto A, Moreno D, Graell M, Baeza I, Otero S, Soutullo CA, Crespo-Facorro B, Ruiz-Sancho A, Desco M, Rojas-Corrales O, Patino A, Carrasco-Marin E, Arango C, CAFEPS: The child and adolescent first-episode psychosis study (CAFEPS): Design and baseline results. Schizophr Res 91:226-237, 2007.
10. Cheer SM, Wagstaff AJ: Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs 18:173-199, 2004.
11. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT: Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 14:372-392, 2004.
12. Citrome L, Jaffe A, Levine J, Lindenmayer JP: Dosing of quetiapine in schizophrenia: How clinical practice differs from registration studies. J Clin Psychiatry 66:1512-1516, 2005.
13. Cohen J: Statistical power analysis for the behavioral sciences. New York, Academic Press, 1977.
14. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM: Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 160:2063-2065, 2003.
15. Correll CU, Frederickson AM, Kane JM, Manu P: Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 89:91-100, 2007.
16. nd edition. London, Chapman and Hall, 1989.
17. Davis JM, Chen N: The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: Combined results of the North American and international trials. J Clin Psychiatry 62:757-771, 2001.
18. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S: Olanzapine for schizophrenia. Chochrane Database Syst Rev CD001359, 2003.
19. Guy W: ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM) 76-338. Rockville MD: Institute of Mental Health, 1977.
20. Hsu JC: The factor analytic approach to simultaneous inference in the general linear model. J Comp Graph Stat 1:151-168, 1972.
21. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276, 1987.
22. Kelly DL, Conley RR: Thyroid function in treatment-resistent schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 66:80-84, 2005.
23. Kopala LC, Good KP, Milliken H, Buiteman C, Woodley H, Rui Q, Whitehorn D, Love L, Balshaw R, Kiss I, Horner WG: Treatment of a first episode of psychotic illness with quetiapine: An analysis of 2 year outcomes. Schizophr Res 81:29-39, 2006.
24. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM, HGDH Study Group: Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 160:1396-404, 2003.
25. Lin D, Wei L, Ying Z: Checking the Cox model with cumulative sums of Martingale-based residuals, Biometrika 80:557-572, 1993.
26. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a crosssectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand (Suppl 334):1-100, 1987.
27. Malla AK, Norman RM, Schmitz N, Manchande R, Béchard-Evans L, Tkhar J, Haricharan R: Predictors of rate and time to remission in first-episode psychosis: A two-year outcome study. Psycholol Med 16:1-10, 2006.
28. McConville BJ, Sorter MT: Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 65 (Suppl):20-29, 2004.
29. McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61:252-260, 2000.
30. Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, Thompson PA: Age at onset and gender of schizophrenic patients in relation to neuroleptic resistence. Am J Psychiatry 154:475-482, 1997.
31. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B: Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 50:79-88, 2001.
32. Perkins D: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of first-episode psychosis: A randomized, double-blind, 52-week comparison. Abstracts of the American Psychiatric Association 2006 Annual Meeting; May 20-25, 2006; Toronto, Ontario, Canada, 2006.
33. Saito E, Correll CU, Gallelli K, McMeniman M, Parikh UH, Malhotra AK, Kafantaris V: A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 14:350-358, 2004.
34. Sajatovic M, Mullen JA, Sweitzer DE: Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 63:1156-1163, 2002.
35. Sato T, Bottlender R, Schroter A, Moeller HJ: Psychopathology of early-onset versus late-onset schizophrenia revisited: An observation of 473 neuroleptic-naive patients before and after first-admission treatments. Schizophr Res 67:175-183, 2004.
36. Schimmelman BG, Paulus S, Schacht M, Schulte-Markwort M, Lambert M: Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol 15:249-258, 2005.
37. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, VanHove I, Eerdekens M, Swyzen W, DeSmedt G, Early Psychosis Global Working Group: Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. Am J Psychiatry 162:947-953, 2005.
38. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M: Study of quetiapine: Efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415-424, 2001.
39. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand (Suppl 212):11-19, 1970.
40. Srisurapanont M, Maneeton B, Maneeton N: Quetiapine for schizophrenia. Cochrane Database Syst. Rev. CD000967, 2004.